Platelets and neurovascular inflammation

Thrombosis and Haemostasis

Volumn 110, Issue 5, 2013, Pages 888-893

  Langer, Harald F ^a   Chavakis, Triantafyllos ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Neuroinflammation; Platelets

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CD36 ANTIGEN; CXCL1 CHEMOKINE; GLYCOPROTEIN IB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; P SELECTIN GLYCOPROTEIN LIGAND 1; TAU PROTEIN; THROMBIN RECEPTOR; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; MOLECULAR INTERACTION; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE;

NEUROINFLAMMATION; PLATELETS;

ALZHEIMER DISEASE; ANIMALS; BLOOD PLATELETS; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; MICE; MULTIPLE SCLEROSIS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84887003951     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-02-0096     Document Type: Article

References (82)

1. Langer HF, Chavakis T. Leukocyte-endothelial interactions in inflammation. J Cell Mol Med 2009; 13: 1211-1220.
2. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
3. von Hundelshausen P, Koenen RR, Weber C. Platelet-mediated enhancement of leukocyte adhesion. Microcirculation 2009; 16: 84-96.
4. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
5. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111: 5271-5281.
6. Ehlers R, Ustinov V, Chen Z, et al. Targeting platelet-leukocyte interactions: identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ibalpha. J Exp Med 2003; 198: 1077-1088.
7. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204.
8. Santoso S, Sachs UJ, Kroll H, et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 2002; 196: 679-691.
9. Chavakis T, Santoso S, Clemetson KJ, et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J Biol Chem 2003; 278: 45375-45381.
10. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085-2093.
11. Simon DI. Inflammation and vascular injury: basic discovery to drug development. Circ J 2012; 76: 1811-1818.
12. Langer HF, Choi EY, Zhou H, et al. Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Circ Res 2012; 110: 1202-1210.
13. Wang Y, Sakuma M, Chen Z, et al. Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation 2005; 112: 2993-3000.
14. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327: 580-583.
15. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13: 463-469.
16. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010; 107: 1047-1057.
17. Mause SF, von Hundelshausen P, Zernecke A, et al. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005; 25: 1512-1518.
18. Vasina E, Heemskerk JW, Weber C, et al. Platelets and platelet-derived microparticles in vascular inflammatory disease. Inflamm Allergy Drug Targets 2010; 9: 346-354.
19. Vasina EM, Cauwenberghs S, Feijge MA, et al. Microparticles from apoptotic platelets promote resident macrophage differentiation. Cell Death Dis 2011; 2: e211.
20. Alexandru N, Popov D, Dragan E, et al. Circulating endothelial progenitor cell and platelet microparticle impact on platelet activation in hypertension associated with hypercholesterolemia. PLoS One 2013; 8: e52058.
21. Amabile N, Rautou PE, Tedgui A, Boulanger CM. Microparticles: key protagonists in cardiovascular disorders. Semin Thromb Hemost 2010; 36: 907-916.
22. Dasgupta SK, Le A, Chavakis T, et al. Developmental endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the endothelium. Circulation 2012; 125: 1664-1672.
23. Zhou H, Lapointe BM, Clark SR, et al. A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide. J Immunol 2006; 177: 8103-8110.
24. Zhou H, Andonegui G, Wong CH, et al. Role of endothelial TLR4 for neutrophil recruitment into central nervous system microvessels in systemic inflammation. J Immunol 2009; 183: 5244-5250.
25. Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007; 204: 571-582.
26. Davalos D, Ryu JK, Merlini M, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 2012; 3: 1227.
27. Carvalho-Tavares J, Hickey MJ, Hutchison J, et al. A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. Circ Res 2000; 87: 1141-1148.
28. von zur Muhlen C, Sibson NR, Peter K, et al. A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest 2008; 118: 1198-1207.
29. Barbier M, Faille D, Loriod B, et al. Platelets alter gene expression profile in human brain endothelial cells in an in vitro model of cerebral malaria. PLoS One 2011; 6: e19651.
30. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-490.
31. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25: 489-495.
32. Patzelt J, Langer HF. Platelets in angiogenesis. Curr Vasc Pharmacol 2012; 10: 570-577.
33. Thornton P, McColl BW, Greenhalgh A, et al. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 2010; 115: 3632-3639.
34. Nieswandt B, Kleinschnitz C, Stoll G. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol 2011; 589: 4115-4123.
35. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 2008; 112: 3555-3562.
36. Kleinschnitz C, Pozgajova M, Pham M, et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323-2330.
37. Langhauser F, Gob E, Kraft P, et al. Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood 2012; 120: 4082-4092.
38. Kleinschnitz C, Schwab N, Kraft P, et al. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood 2010; 115: 3835-3842.
39. Kleinschnitz C, Kraft P, Dreykluft A, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood 2013; 121: 679-691.
40. De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke 2012; 43: 599-606.
41. Kleinschnitz C, Pozgajova M, Pham M, et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323-2330.
42. Elvers M, Stegner D, Hagedorn I, et al. Impaired alpha(IIb)beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1. Sci Signal 2010; 3: 1-10.
43. Doeuvre L, Plawinski L, Toti F, et al. Cell-derived microparticles: a new challenge in neuroscience. J Neurochem 2009; 110: 457-468.
44. Simak J, Gelderman MP, Yu H, et al. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost 2006; 4: 1296-1302.
45. Lukasik M, Rozalski M, Luzak B, et al. Platelet activation and reactivity in the convalescent phase of ischaemic stroke. Thromb Haemost 2010; 103: 644-650.
46. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-344.
47. Sardi F, Fassina L, Venturini L, et al. Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev 2011; 11: 149-153.
48. Claeysen S, Cochet M, Donneger R, et al. Alzheimer culprits: cellular crossroads and interplay. Cell Signal 2012; 24: 1831-1840.
49. Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell 2012; 148: 1188-1203.
50. Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 2010; 16: 1210-1214.
51. Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012; 367: 1497-1507.
52. Nussbaum JM, Seward ME, Bloom GS. Alzheimer disease: A tale of two prions. Prion 2012; 7: 14-19.
53. de Silva HA, Aronson JK, Grahame-Smith DG, et al. Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet 1998; 352: 1590-1593.
54. Sevush S, Jy W, Horstman LL, et al. Platelet activation in Alzheimer disease. Arch Neurol 1998; 55: 530-536.
55. Bush AI, Tanzi RE. Alzheimer disease-related abnormalities of amyloid beta precursor protein isoforms in the platelet: the brain's delegate in the periphery? Arch Neurol 1998; 55: 1179-1180.
56. Catricala' S, Torti M, Ricevuti G. Alzheimer disease and platelets: how's that relevant. Immun Ageing 2012; 9: 20.
57. Skovronsky DM, Lee VM, Pratico D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 2001; 276: 17036-17043.
58. Zainaghi IA, Talib LL, Diniz BS, et al. Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease. J Neural Transm 2012; 119: 815-819.
59. Vignini A, Sartini D, Morganti S, et al. Platelet amyloid precursor protein isoform expression in Alzheimer's disease: evidence for peripheral marker. Int J Immunopathol Pharmacol 2011; 24: 529-534.
60. Laske C, Leyhe T, Stransky E, et al. Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer's disease. J Psychiatr Res 2008; 42: 746-751.
61. Stellos K, Panagiota V, Kogel A, et al. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer's disease patients. J Cereb Blood Flow Metab 2010; 30: 1817-1820.
62. Neumann K, Farias G, Slachevsky A, et al. Human platelets tau: a potential peripheral marker for Alzheimer's disease. J Alzheimers Dis 2011; 25: 103-109.
63. Ursini F, Davies KJ, Maiorino M, et al. Atherosclerosis: another protein misfolding disease? Trends Mol Med 2002; 8: 370-374.
64. Herczenik E, Bouma B, Korporaal SJ, et al. Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol 2007; 27: 1657-1665.
65. Ray DM, Spinelli SL, O'Brien JJ, et al. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease. BioDrugs 2006; 20: 231-241.
66. Bishop-Bailey D. The platelet as a model system for the acute actions of nuclear receptors. Steroids 2010; 75: 570-575.
67. Sodhi RK, Singh N, Jaggi AS. Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease. Naunyn Schmiedebergs Arch Pharmacol 2011; 384: 115-124.
68. Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012; 2: CD006378.
69. Thoonsen H, Richard E, Bentham P, et al. Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern? Stroke 2010; 41: 2690-2692.
70. Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol 2004; 5: 575-581.
71. Steinman L, Martin R, Bernard C, et al. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci 2002; 25: 491-505.
72. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4: 510-518.
73. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66.
74. Graesser D, Solowiej A, Bruckner M, et al. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest 2002; 109: 383-392.
75. Vajkoczy P, Laschinger M, Engelhardt B. Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest 2001; 108: 557-565.
76. Steinman L. The discovery of natalizumab, a potent therapeutic for multiple sclerosis. J Cell Biol 2012; 199: 413-416.
77. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500-508.
78. Doring A, Wild M, Vestweber D, et al. E-and P-selectin are not required for the development of experimental autoimmune encephalomyelitis in C57BL/6 and SJL mice. J Immunol 2007; 179: 8470-8479.
79. Bullard DC, Hu X, Schoeb TR, Axtell RC, Raman C, Barnum SR. Critical requirement of CD11b (Mac-1) on T cells and accessory cells for development of experimental autoimmune encephalomyelitis. J Immunol 2005; 175: 6327-6333.
80. Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 2008; 5: 27.
81. Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076-1081.
82. Horstman LL, Jy W, Ahn YS et al. Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation 2010; 7: 10.